{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:22:40Z","timestamp":1790648560092,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013432","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000}}],"reference-count":72,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013432.pub2","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T02:53:25Z","timestamp":1607568805000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-IL-5 therapies for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2020","author":[{"given":"Tim","family":"Donovan","sequence":"additional","affiliation":[{"name":"Medical and Sport Sciences; University of Cumbria; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Milan","sequence":"additional","affiliation":[{"name":"Medical School; Lancaster University; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Manchester University NHS Foundation Trust; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Banchoff","sequence":"additional","affiliation":[{"name":"PHRI; St George's, University of London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; North West Lung Centre, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Crossingham","sequence":"additional","affiliation":[{"name":"East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"issue":"Suppl 58","key":"10.1002\/14651858.CD013432.pub2-BIB0001|cit1","first-page":"P2818","article-title":"A phase 2a study of benralizumab in adults with COPD [Abstract]","volume":"44","author":"Brightling","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0002|cit2","first-page":"P2818","article-title":"Late-breaking abstract: a phase 2a study of benralizumab in adults with COPD","volume":"44","author":"Brightling","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0003|cit3","first-page":"A3771","article-title":"A phase 2a study of benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, in adults with chronic obstructive pulmonary disease and sputum eosinophilia [Abstract]","volume":"189","author":"Brightling","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013432.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"PA2118","DOI":"10.1183\/13993003.congress2015.PA2118","article-title":"Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia","volume":"46","author":"Damera","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0006|cit6","first-page":"PA2118","article-title":"Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with chronic obstructive pulmonary disease and sputum eosinophilia","volume":"191","author":"Damera","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0007|cit7","unstructured":"A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophilia who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-020127-52-GB"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0008|cit8","unstructured":"A study to evaluate the effectiveness of MEDI-563 in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/nct01227278"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0009|cit9","first-page":"S95","article-title":"Pharmacokinetics and pharmacodynamics of benralizumab in subjects with moderate-to-severe chronic obstructive pulmonary disease","volume":"97","author":"Yan","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD013432.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1602486","DOI":"10.1183\/13993003.02486-2016","article-title":"A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis","volume":"49","author":"Dasgupta","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0011|cit11","unstructured":"Dasgupta A Kjarsgaard M Capaldi D Radford K Aleman F Parraga G Mepolizumab in COPD with eosinophilic bronchitis: a randomized clinical trial. European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London 2016 PA305 10.1183\/13993003.congress-2016.PA305"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013432.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"AB392","DOI":"10.1016\/j.jaci.2015.12.1215","article-title":"Mepolizumab in COPD with eosinophilic bronchitis: a randomized clinical trial","volume":"137","author":"Nair","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0013|cit13","unstructured":"Mepolizumab in chronic obstructive pulmonary diseases (COPD) with eosinophilic bronchitis clinicaltrials.gov\/show\/NCT01463644"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0014|cit14","unstructured":"Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-004298-28-SE"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0015|cit15","first-page":"1","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"25","author":"Jose","year":"2018","journal-title":"Journal of Clinical Outcomes Management"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0016|cit16","unstructured":"Study to evaluate efficacy and safety of mepolizumab for frequently exacerbating chronic obstructive pulmonary disease (COPD) patients clinicaltrials.gov\/show\/nct02105948"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0017|cit17","unstructured":"Study 117106: Mepolizumab vs. placebo as add-on treatment for frequently exacerbating COPD patients www.who.int\/trialsearch\/Trial2.aspx?TrialID=PER-013-14"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013432.pub2-BIB0018|cit18","first-page":"OA3194","article-title":"Mepolizumab reduces exacerbations in eosinophilic COPD","volume":"50","author":"Sciurba","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013432.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"OA3194","DOI":"10.1183\/1393003.congress-2017.OA3194","article-title":"Late breaking abstract - mepolizumab reduces exacerbations in eosinophilic COPD","volume":"50","author":"Sciurba","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0020|cit20","unstructured":"Study MEA117113: mepolizumab vs. placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level www.drks.de\/DRKS00007259"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0021|cit21","unstructured":"English study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004297-98\/results"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0022|cit22","unstructured":"Efficacy and safety of mepolizumab as an add-on treatment in chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/nct02105961"},{"issue":"17","key":"10.1002\/14651858.CD013432.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0024|cit24","first-page":"PA1366","article-title":"Dose-ranging study of mepolizumab in eosinophilic COPD","volume":"50","author":"Pavord","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013432.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"PA1366","DOI":"10.1183\/1393003.congress-2017.PA1366","article-title":"Late breaking abstract - dose-ranging study of mepolizumab in eosinophilic COPD","volume":"50","author":"Pavord","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD013432.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0027|cit27","unstructured":"Efficacy and safety of 2 benralizumab doses in moderate to very severe COPD patients with prior exacerbation history www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-004590-27-AT"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0028|cit28","unstructured":"Benralizumab efficacy in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history clinicaltrials.gov\/show\/NCT02138916"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0029|cit29","unstructured":"Efficacy and safety of benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history clinicaltrials.gov\/show\/NCT02155660"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0030|cit30","unstructured":"A randomised, double-blind, double dummy, chronic dosing (56 week) placebo-controlled, parallel group, multicentre, phase iii study to evaluate the efficacy and safety of 3 doses of benralizumab (medi-563) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of COPD exacerbations (Terranova) www.who.int\/trialsearch\/Trial2.aspx?TrialID=PER-040-14"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.rmed.2019.07.004","article-title":"No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia","volume":"155","author":"Condreay","year":"2019","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013432.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12931-018-0968-8","article-title":"Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases","volume":"20","author":"Sridhar","year":"2019","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0033|cit33","unstructured":"Efficacy and safety of benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of frequent exacerbations clinicaltrials.gov\/show\/nct04053634"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0034|cit34","unstructured":"Mepolizumab for COPD hospital eosinophilic admissions pragmatic trial (COPD-HELP) clinicaltrials.gov\/show\/NCT04075331"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0035|cit35","unstructured":"Acute exacerbations treated with benralizumab (The ABRA Study) (ABRA) clinicaltrials.gov\/show\/nct04098718"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0036|cit36","unstructured":"Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE) clinicaltrials.gov\/ct2\/show\/NCT04133909"},{"issue":"8","key":"10.1002\/14651858.CD013432.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3390\/ijms19082244","article-title":"Anti-TNF therapy in Crohn's disease","volume":"19","author":"Adegbola","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1002\/14651858.CD013432.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013432.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00062614","article-title":"Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis","volume":"44","author":"Bafadhel","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD013432.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0041|cit41","unstructured":"British Lung Foundation Chronic obstructive pulmonary disease (COPD) statistics statistics.blf.org.uk\/copd"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0042|cit42","unstructured":"Cochrane Airways Trials Register airways.cochrane.org\/trials-register"},{"issue":"2","key":"10.1002\/14651858.CD013432.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2016.10.003","article-title":"Eosinophils in COPD exacerbations are associated with increased readmissions","volume":"151","author":"Couillard","year":"2017","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD013432.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013432","article-title":"Anti-IL5 therapies for chronic obstructive pulmonary disease","author":"Donovan","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013432.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.trsl.2015.08.004","article-title":"Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease","volume":"167","author":"Durham","year":"2016","journal-title":"Translational Research"},{"issue":"9","key":"10.1002\/14651858.CD013432.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 therapies for asthma","author":"Farne","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0047|cit47","unstructured":"2019 GINA Report, Global Strategy for Asthma Management and Prevention ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf"},{"issue":"5","key":"10.1002\/14651858.CD013432.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0049|cit49","unstructured":"2020 Global Strategy for Prevention, Diagnosis and Management of COPD goldcopd.org\/wp-content\/uploads\/2019\/12\/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0050|cit50","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2019"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0051|cit51","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"26","key":"10.1002\/14651858.CD013432.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013432.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner\u2019s guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0054|cit54","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit; 2017 September 13-16; Cape Town, South Africa 2017"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0055|cit55","unstructured":"Milan S Prednisone surrogate in the trial Email to: P Nair"},{"issue":"7","key":"10.1002\/14651858.CD013432.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2016.10.016","article-title":"Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation","volume":"169","author":"Nixon","year":"2017","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0058|cit58","unstructured":"Noel-Storr AH Project Transform team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live; 2018 June 18-20; Oxford, UK 2018"},{"issue":"1","key":"10.1002\/14651858.CD013432.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003559.pub4","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013432.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013432.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/thoraxjnl-2015-207228","article-title":"Two lovely black eyes; oh, what a surprise!","volume":"70","author":"Pavord","year":"2015","journal-title":"Thorax"},{"issue":"17","key":"10.1002\/14651858.CD013432.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013432.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.jaci.2018.04.020","article-title":"Biologics and chronic obstructive pulmonary disease","volume":"141","author":"Pavord","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0064|cit64","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"1","key":"10.1002\/14651858.CD013432.pub2-BIB0065|cit65","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Shironjit","year":"2006","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"6","key":"10.1002\/14651858.CD013432.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD013432.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD013432.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"759A","DOI":"10.1016\/j.chest.2018.08.684","article-title":"Anti-IL-5 agents in the treatment of eosinophilic COPD: a systematic review and meta-analysis","volume":"154","author":"Tan","year":"2018","journal-title":"Chest"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living systematic review network. Living systematic reviews: 2. Combining human and machine effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD013432.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0071|cit71","unstructured":"World Health Organization Chronic obstructive pulmonary disease (COPD) www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)"},{"key":"10.1002\/14651858.CD013432.pub2-BIB0072|cit72","unstructured":"World Health Organization Burden of COPD www.who.int\/respiratory\/copd\/burden\/en\/"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T08:31:24Z","timestamp":1685521884000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013432.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013432.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}